Diabetic Nephropathy – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Diabetic Nephropathy – Pipeline Review, H1 2017’, provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy

– The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Allergan Plc

Antisense Therapeutics Ltd

Aptevo Therapeutics Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BLR Bio LLC

Boehringer Ingelheim GmbH

Cellmid Ltd

ChemoCentryx Inc

CSL Ltd

Daiichi Sankyo Company Ltd

DiaMedica Therapeutics Inc

Dynamis Therapeutics Inc

Galectin Therapeutics Inc

GenKyoTex SA

Gilead Sciences Inc

GNI Group Ltd

Islet Sciences Inc

Jenrin Discovery Inc

Johnson & Johnson

Mallinckrodt Plc

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

MorphoSys AG

Novartis AG

Noxxon Pharma AG

Omeros Corp

PhiloGene Inc

PhytoHealth Corp

ProMetic Life Sciences Inc

RegenMedTX LLC

Serodus ASA

Teijin Pharma Ltd

Theravance Biopharma Inc

Variant Pharmaceuticals Inc

Vascular Pharmaceuticals Inc

Vicore Pharma AB

XORTX Pharma Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Nephropathy - Overview 9

Diabetic Nephropathy - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Diabetic Nephropathy - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Diabetic Nephropathy - Companies Involved in Therapeutics Development 31

AbbVie Inc 31

Allergan Plc 31

Antisense Therapeutics Ltd 32

Aptevo Therapeutics Inc 32

Araim Pharmaceuticals Inc 33

Arena Pharmaceuticals Inc 33

Astellas Pharma Inc 34

AstraZeneca Plc 34

Bayer AG 35

BLR Bio LLC 35

Boehringer Ingelheim GmbH 36

Cellmid Ltd 36

ChemoCentryx Inc 37

CSL Ltd 37

Daiichi Sankyo Company Ltd 38

DiaMedica Therapeutics Inc 38

Dynamis Therapeutics Inc 39

Galectin Therapeutics Inc 39

GenKyoTex SA 40

Gilead Sciences Inc 40

GNI Group Ltd 41

Islet Sciences Inc 41

Jenrin Discovery Inc 42

Johnson & Johnson 42

Mallinckrodt Plc 43

Mesoblast Ltd 43

Mitsubishi Tanabe Pharma Corp 44

MorphoSys AG 44

Novartis AG 45

Noxxon Pharma AG 45

Omeros Corp 46

PhiloGene Inc 46

PhytoHealth Corp 47

ProMetic Life Sciences Inc 47

RegenMedTX LLC 48

Serodus ASA 48

Teijin Pharma Ltd 49

Theravance Biopharma Inc 49

Variant Pharmaceuticals Inc 50

Vascular Pharmaceuticals Inc 50

Vicore Pharma AB 50

XORTX Pharma Corp 51

Diabetic Nephropathy - Drug Profiles 52

11-RVIVIT - Drug Profile 52

A-717 - Drug Profile 53

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 54

APD-371 - Drug Profile 55

APX-115 - Drug Profile 56

ASP-8232 - Drug Profile 57

atesidorsen sodium - Drug Profile 58

atrasentan hydrochloride - Drug Profile 66

BI-703704 - Drug Profile 68

BL-5923 - Drug Profile 69

BLR-200 - Drug Profile 70

C-21 - Drug Profile 71

canagliflozin - Drug Profile 74

CCX-140 - Drug Profile 81

Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 85

cenicriviroc mesylate - Drug Profile 87

cibinetide - Drug Profile 95

corticotropin - Drug Profile 98

CSL-346 - Drug Profile 100

Cyndacel-M - Drug Profile 101

DM-299 - Drug Profile 103

Drugs for Diabetic Nephropathy - Drug Profile 104

DT-23552 - Drug Profile 105

DYN-12 - Drug Profile 106

emapticap pegol - Drug Profile 108

esaxerenone - Drug Profile 111

finerenone - Drug Profile 114

GKT-136901 - Drug Profile 116

GKT-831 - Drug Profile 117

GLY-230 - Drug Profile 120

GRMD-02 - Drug Profile 121

GS-444217 - Drug Profile 134

IP-9 - Drug Profile 135

JD-5037 - Drug Profile 136

JNJ-39933673 - Drug Profile 137

MG-132 - Drug Profile 138

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 139

MOR-107 - Drug Profile 141

MPC-300IV - Drug Profile 142

MT-3995 - Drug Profile 148

Orbcel-M - Drug Profile 149

oxypurinol - Drug Profile 150

PBI-4050 - Drug Profile 151

PBI-4425 - Drug Profile 158

PBI-4547 - Drug Profile 159

PHN-033 - Drug Profile 160

pirfenidone - Drug Profile 161

Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology - Drug Profile 163

SER-150 - Drug Profile 164

Small Molecules for Diabetic Nephropathy - Drug Profile 167

Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 168

SP-20202 - Drug Profile 169

TBE-31 - Drug Profile 170

TD-0714 - Drug Profile 171

TD-1439 - Drug Profile 173

TMX-049 - Drug Profile 174

TNFR x TWEAKR - Drug Profile 175

VAR-400 - Drug Profile 176

VPI-2690B - Drug Profile 177

VS-105 - Drug Profile 178

Wnt-001 - Drug Profile 179

XRX-108 - Drug Profile 180

XRX-221 - Drug Profile 181

Diabetic Nephropathy - Dormant Projects 182

Diabetic Nephropathy - Discontinued Products 184

Diabetic Nephropathy - Product Development Milestones 185

Featured News & Press Releases 185

Appendix 195

Methodology 195

Coverage 195

Secondary Research 195

Primary Research 195

Expert Panel Validation 195

Contact Us 195

Disclaimer 196

List of Tables

List of Tables

Number of Products under Development for Diabetic Nephropathy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Diabetic Nephropathy – Pipeline by AbbVie Inc, H1 2017

Diabetic Nephropathy – Pipeline by Allergan Plc, H1 2017

Diabetic Nephropathy – Pipeline by Antisense Therapeutics Ltd, H1 2017

Diabetic Nephropathy – Pipeline by Aptevo Therapeutics Inc, H1 2017

Diabetic Nephropathy – Pipeline by Araim Pharmaceuticals Inc, H1 2017

Diabetic Nephropathy – Pipeline by Arena Pharmaceuticals Inc, H1 2017

Diabetic Nephropathy – Pipeline by Astellas Pharma Inc, H1 2017

Diabetic Nephropathy – Pipeline by AstraZeneca Plc, H1 2017

Diabetic Nephropathy – Pipeline by Bayer AG, H1 2017

Diabetic Nephropathy – Pipeline by BLR Bio LLC, H1 2017

Diabetic Nephropathy – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Diabetic Nephropathy – Pipeline by Cellmid Ltd, H1 2017

Diabetic Nephropathy – Pipeline by ChemoCentryx Inc, H1 2017

Diabetic Nephropathy – Pipeline by CSL Ltd, H1 2017

Diabetic Nephropathy – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Diabetic Nephropathy – Pipeline by DiaMedica Therapeutics Inc, H1 2017

Diabetic Nephropathy – Pipeline by Dynamis Therapeutics Inc, H1 2017

Diabetic Nephropathy – Pipeline by Galectin Therapeutics Inc, H1 2017

Diabetic Nephropathy – Pipeline by GenKyoTex SA, H1 2017

Diabetic Nephropathy – Pipeline by Gilead Sciences Inc, H1 2017

Diabetic Nephropathy – Pipeline by GNI Group Ltd, H1 2017

Diabetic Nephropathy – Pipeline by Islet Sciences Inc, H1 2017

Diabetic Nephropathy – Pipeline by Jenrin Discovery Inc, H1 2017

Diabetic Nephropathy – Pipeline by Johnson & Johnson, H1 2017

Diabetic Nephropathy – Pipeline by Mallinckrodt Plc, H1 2017

Diabetic Nephropathy – Pipeline by Mesoblast Ltd, H1 2017

Diabetic Nephropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Diabetic Nephropathy – Pipeline by MorphoSys AG, H1 2017

Diabetic Nephropathy – Pipeline by Novartis AG, H1 2017

Diabetic Nephropathy – Pipeline by Noxxon Pharma AG, H1 2017

Diabetic Nephropathy – Pipeline by Omeros Corp, H1 2017

Diabetic Nephropathy – Pipeline by PhiloGene Inc, H1 2017

Diabetic Nephropathy – Pipeline by PhytoHealth Corp, H1 2017

Diabetic Nephropathy – Pipeline by ProMetic Life Sciences Inc, H1 2017

Diabetic Nephropathy – Pipeline by RegenMedTX LLC, H1 2017

Diabetic Nephropathy – Pipeline by Serodus ASA, H1 2017

Diabetic Nephropathy – Pipeline by Teijin Pharma Ltd, H1 2017

Diabetic Nephropathy – Pipeline by Theravance Biopharma Inc, H1 2017

Diabetic Nephropathy – Pipeline by Variant Pharmaceuticals Inc, H1 2017

Diabetic Nephropathy – Pipeline by Vascular Pharmaceuticals Inc, H1 2017

Diabetic Nephropathy – Pipeline by Vicore Pharma AB, H1 2017

Diabetic Nephropathy – Pipeline by XORTX Pharma Corp, H1 2017

Diabetic Nephropathy – Dormant Projects, H1 2017

Diabetic Nephropathy – Dormant Projects, H1 2017 (Contd..1), H1 2017

Diabetic Nephropathy – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Diabetic Nephropathy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports